Abstract:Abstract T-cell acute lymphoblastic leukemia (T-ALL) is a common hematological malignancy associated with poor prognosis and significant risk of relapse. Loss of PTEN function due to mutations or deletions is common in primary T-ALL samples and is associated with resistance to therapeutic agents. We previously developed a VEC-Cre+;Ptenloxp/loxp (Pten null) T-ALL model to investigate the molecular and cellular mechanisms underlying T-ALL pathogenesis and resistance to therapy. Pten-null T-ALL develops after acquisition of a T cell receptor α/δ-c-myc translocation that causes c-Myc over-expression, and the leukemia-initiating cells, or leukemia stem cells (LSCs), are enriched in a c-kitmidCD3+ subpopulation. The goal of our current study is to develop improved therapeutic approaches to target LSCs and eliminate T-ALL. We hypothesize that small molecule inhibitors that target molecular lesions and pathways required for the development and survival of Pten null LSCs and T-ALL may be potent in eliminating LSCs and abolishing T-ALL. Rapamycin, an inhibitor of the PI3K downstream kinase mTOR, can suppress leukemia development in Pten null pre-leukemic mice, but is insufficient to eliminate LSCs and T-ALL. Therefore, we are investigating the therapeutic utility of combinational therapies that co-target multiple deregulated pathways that are critical for LSC formation and T-ALL survival. We found that combination treatment of Pten null T-ALL mice with rapamycin and VX-680, an Aurora kinase inhibitor shown to have synthetic lethality with Myc over-expression, causes robust elimination of leukemia blasts and significantly diminishes the LSC population. Functional studies for leukemia-initiating-cell activity using transplantation of treated bone marrow into NOD-SCID-IL2rγ-/-(NSG) recipients showed that dual treatment reduced leukemia-initiating-cell activity in bone marrow by at least 100-fold in comparison to single agent alone. Importantly, a large portion of Pten null T-ALL LSCs are actively cycling (~50% in S-phase), which may contribute to the mechanism underlying the efficacy of VX-680. We have developed a T-ALL in vitro culture system derived from primary Pten null T-ALL mice to conduct more detailed evaluation of the cellular and biochemical effects of rapamycin and VX-680, perform mechanistic analysis, and screen additional cell cycle-directed and Myc-targeted agents. We found that Pten null T-ALL is highly sensitive to killing by the CDK1 inhibitor purvalanol and JQ1, a bromodomain inhibitor reported to down-regulate c-myc expression that is suitable for use in vivo. Rapamycin and JQ1 combination treatment of Pten null T-ALL mice causes a significant reduction in both the leukemia blast and LSC populations, similar to the effects of rapamycin and VX-680 combination therapy. Our results highlight the importance of understanding the mechanisms underlying T-ALL development and survival and show potent synthetic lethality of PI3K and Myc pathway co-inhibition in PTEN null T-ALL LSCs. Importantly, such targeted combination therapy may offer an improved therapeutic approach to treat human T-ALL. Citation Format: Suzanne Schubbert, Anjelica Cardenas, Christopher Wei, Lingda Ma, Consuelo Garcia, Wei Guo, Hong Wu. Co-inhibition of PI3K and Myc pathways is synthetic lethal to PTEN null T-ALL leukemia-initiating cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities; May 17-20, 2013; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(5 Suppl):Abstract nr B12.

PTEN is fundamental for elimination of leukemia stem cells mediated by GSK126 targeting EZH2 in chronic myelogenous leukemia.

Leukemia Stem Cells: the Root of Chronic Myeloid Leukemia

Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.

Chemoresistant Leukemia-Initiating Cell Expansion is Inhibited by Targeting Oncogenic Self-Renewal

Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells.

Abstract 2016: Combined targeting of epigenetic mechanisms has superior efficacy against human mantle cell lymphoma cells

Overcoming Wnt–β-catenin Dependent Anticancer Therapy Resistance in Leukaemia Stem Cells

Stromal Cells Attenuate the Cytotoxicity of Imatinib on Philadelphia Chromosome-Positive Leukemia Cells by Up-Regulating the VE-cadherin/β-catenin Signal

Targeting USP47 Overcomes Tyrosine Kinase Inhibitor Resistance and Eradicates Leukemia Stem/progenitor Cells in Chronic Myelogenous Leukemia

Genome-wide CRISPR screening identifies critical role of phosphatase and tensin homologous (PTEN) in sensitivity of acute myeloid leukemia to chemotherapy

Bcl-2 inhibition combined with PPARα activation synergistically targets leukemic stem cell-like cells in acute myeloid leukemia

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease

Abstract B12: Co-inhibition of PI3K and Myc Pathways is Synthetic Lethal to PTEN Null T-ALL Leukemia-Initiating Cells

PTEN Maintains Haematopoietic Stem Cells and Acts in Lineage Choice and Leukaemia Prevention

TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN

Effects of Enhancer of Zeste Homolog 2 Inhibitor GSK126 on the Cell Proliferation and Apoptosis of Acute Leukemia and Lymphoma Cells in Vitro

PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway

PB1652 ABERRANT EZH2 HIGH EXPRESSION IN THE PATIENTS WITH ACUTE LEUKEMIA AND EFFECT OF A NOVEL EZH2 INHIBITOR GSK126 ON CELL PROLIFERATION AND APOPTOSIS OF THE MALIGNANT CELLS

Suppression of Leukemia Development Caused by Pten Loss